PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders) (PEARL)
Sponsor: Duke University
A PHASE1 clinical study on Gaucher Disease, Type 2 and Gaucher Disease, Type 3, this trial is actively recruiting participants. The trial is conducted by Duke University and has accumulated 13 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Apr 2025 — Present [monthly]
Recruiting PHASE1
-
Feb 2025 — Apr 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Sep 2022 — Oct 2023 [monthly]
Recruiting PHASE1
-
May 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
May 2021 — May 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
Sep 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Duke University
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .